DHEA-S Blood Test: The Adrenal Reserve Marker That Predicts Longevity

Of all the hormones that decline with age, DHEA-S is among the most precipitous and the most clinically overlooked. While cortisol and thyroid function receive regular attention on functional medicine panels, DHEA-S — the sulphated form of dehydroepiandrosterone — is often absent from routine testing despite being the most abundant adrenal steroid in the human body and one of the most reliable biological age markers available.

For practitioners and individuals tracking long-term health, DHEA-S offers a window into adrenal reserve, HPA axis function, and systemic resilience that few other single markers can match.

What Is DHEA-S?

DHEA-S is the sulphated (storage) form of DHEA, produced almost entirely by the zona reticularis of the adrenal cortex. The sulphate group makes it water-soluble, dramatically extends its half-life (12–24 hours versus 15–30 minutes for free DHEA), and maintains it at blood concentrations roughly 300–500 times higher than free DHEA. This stability is precisely why DHEA-S is preferred over DHEA for blood testing — it provides a far more reliable snapshot of adrenal androgen output without the wide intraday fluctuations that make free DHEA measurements inconsistent.

Once released from the adrenals, DHEA-S is converted peripherally to DHEA and then to active sex hormones including testosterone and oestradiol. In postmenopausal women, peripheral conversion of adrenal DHEA-S becomes the primary source of both androgens and oestrogens — making adrenal status centrally important to hormonal health in later life.

DHEA-S is not classically considered a "stress hormone" in the way cortisol is, but it is profoundly linked to the same axis. ACTH from the pituitary stimulates both cortisol and DHEA-S production, and the ratio between the two reflects the balance between catabolic (cortisol-driven) and anabolic (DHEA-driven) physiology.

The Age-Related Decline

Few biological parameters are as predictably age-dependent as DHEA-S. Peak levels occur in the mid-20s, typically between 250–400 µg/dL in men and 150–300 µg/dL in women. From around age 30, DHEA-S falls at approximately 2–3% per year — roughly 25% per decade. By age 70, most individuals have DHEA-S levels around 10–20% of their youthful peak.

This decline — termed "adrenopause" — occurs in the absence of any identifiable disease process. It is simply a feature of normal human ageing. Unlike menopause or andropause, adrenopause produces no acute symptomatic event, which is one reason it receives less clinical attention. The consequences are nonetheless meaningful: DHEA-S decline tracks closely with age-related decline in key biomarkers, immune function, body composition, and cognitive reserve.

What makes this clinically actionable is that individuals of the same chronological age show enormous variation in DHEA-S levels. A 50-year-old with a DHEA-S of 280 µg/dL is physiologically different from one at 80 µg/dL — and the research suggests their long-term outcomes diverge accordingly.

What Low DHEA-S Indicates

Low DHEA-S for age is rarely a diagnosis in itself but is a reliable signal of several underlying conditions:

Adrenal insufficiency. Primary adrenal insufficiency (Addison's disease) and secondary adrenal insufficiency (pituitary or hypothalamic dysfunction) both suppress DHEA-S production alongside cortisol. DHEA-S below 40 µg/dL in adults under 50 should raise suspicion of adrenal insufficiency and prompt morning cortisol and ACTH testing.

HPA axis dysfunction. Chronic psychological stress, poor sleep, and high allostatic load can progressively exhaust adrenal androgen output while cortisol remains relatively preserved. This pattern — low DHEA-S with normal or elevated cortisol — is sometimes called "adrenal fatigue" in integrative medicine circles, though the mechanistic term "HPA axis dysregulation" is more precise. The cortisol to DHEA ratio is a useful marker here: a high cortisol-to-DHEA-S ratio suggests catabolic dominance and impaired physiological resilience.

Accelerated biological ageing. Multiple large epidemiological studies have found that DHEA-S levels below age-adjusted expectations are associated with faster biological ageing, reduced immune competence, and higher all-cause mortality risk. The Baltimore Longitudinal Study of Aging and the MRFIT cohort both found that lower DHEA-S predicted earlier mortality in middle-aged men, independent of conventional cardiovascular risk factors.

Glucocorticoid use. Exogenous corticosteroids — prednisone, dexamethasone, and even inhaled corticosteroids at high doses — suppress ACTH and consequently suppress adrenal DHEA-S production. Low DHEA-S is virtually universal in individuals on chronic oral corticosteroid therapy.

Severe illness and critical care. DHEA-S plummets during serious illness, surgery, and ICU admission. It recovers slowly — and in some individuals, incompletely — suggesting a persistent shift in adrenal prioritisation toward cortisol output over anabolic androgen production.

What High DHEA-S Indicates

Elevated DHEA-S is less common in the general population but clinically significant when present:

Adrenal tumours. Adrenocortical carcinoma and androgen-producing adrenal adenomas are among the most important causes of markedly elevated DHEA-S. DHEA-S above 700 µg/dL in an adult warrants imaging. More modest elevations in the 400–600 µg/dL range can still reflect adrenal pathology and merit investigation.

Congenital adrenal hyperplasia (CAH). Non-classical CAH due to 21-hydroxylase deficiency is an under-diagnosed cause of moderately elevated DHEA-S, particularly in women presenting with hirsutism, acne, and menstrual irregularity. It can be confirmed with a stimulated 17-hydroxyprogesterone measurement.

Polycystic ovary syndrome (PCOS). Approximately 25–30% of women with PCOS have elevated DHEA-S, reflecting the adrenal androgen excess component of the condition alongside ovarian androgen production.

Acute stress response. Acutely elevated DHEA-S can reflect a short-term adaptive stress response, though sustained elevations rarely result from stress alone.

Optimal vs. Laboratory Reference Ranges

Standard laboratory reference ranges for DHEA-S are broad by design, spanning multiple decades of life and substantial individual variation. In Australia, most labs report a single adult reference range that encompasses a wide span — for example, 35–430 µg/dL for men — which is clinically unhelpful for detecting age-inappropriate decline.

Functional medicine practitioners use age-stratified optimal ranges, which are considerably narrower:

Men aged 40–50:

• Lab reference range: approximately 35–430 µg/dL
• Functional optimal range: 200–350 µg/dL
• Below 150 µg/dL at this age warrants investigation

Men aged 50–60:

• Functional optimal range: 150–280 µg/dL

Women aged 40–50:

• Lab reference range: approximately 35–300 µg/dL
• Functional optimal range: 130–250 µg/dL

Women aged 50–60:

• Functional optimal range: 80–190 µg/dL

The key principle is that "within the lab reference range" does not mean "optimal for age." A 45-year-old man with a DHEA-S of 60 µg/dL is technically within some laboratories' published range but is at a level more consistent with a 70–75-year-old. Interpreting results without age-stratified context misses the clinical signal entirely.

The Longevity Research

The epidemiological literature linking DHEA-S to longevity outcomes is among the most consistent in ageing science:

Cardiovascular mortality. A landmark study published in the New England Journal of Medicine found that men with higher DHEA-S had significantly lower cardiovascular mortality over a 12-year follow-up, with a dose-response relationship across the DHEA-S range. Subsequent meta-analyses confirmed this association, with lower DHEA-S predicting incident coronary artery disease independent of traditional risk factors.

Cognitive decline. Several prospective cohort studies have found that lower DHEA-S is associated with faster cognitive decline, higher risk of Alzheimer's disease, and reduced processing speed. Age-adjusted DHEA-S levels have been shown to predict cognitive function better than chronological age alone in some study populations.

Immune function. DHEA-S appears to modulate Th1/Th2 immune balance and oppose the immunosuppressive effects of cortisol. Lower DHEA-S is associated with reduced vaccine responsiveness and higher rates of infectious illness in older adults.

All-cause mortality. The Rancho Bernardo Study, a large community-based cohort, found that men in the lowest quartile of DHEA-S had approximately double the all-cause mortality risk over 19 years compared to men in the highest quartile, after adjusting for age, adiposity, and chronic disease.

It is important to note that these are observational associations. Whether low DHEA-S causes poorer outcomes or simply reflects underlying biological deterioration that itself drives mortality is not fully resolved. Supplementation trials have yielded more modest and inconsistent results, which suggests that DHEA-S may be as much a marker as a mechanistic driver of accelerated ageing.

Supplementation Evidence

DHEA is available over the counter in the United States but is a Schedule 4 prescription-only medicine in Australia. DHEA supplementation in Australia therefore requires a prescription and is typically initiated by an endocrinologist or anti-ageing medicine physician.

The evidence base for DHEA supplementation is encouraging but not definitive:

Older adults with confirmed low DHEA-S. The DHEA and Well-being (DAWN) trial and other randomised studies found that DHEA supplementation at 50 mg/day improved bone density, physical performance, and quality of life in older individuals with documented adrenal insufficiency or age-related adrenal decline. Effects were more consistent in women than men, likely because women lose a greater proportion of their sex hormone production to adrenal sources as they age.

Cognitive effects. A small number of randomised controlled trials suggest modest improvements in memory and mood with DHEA supplementation in elderly individuals with low baseline levels. Effect sizes are generally small and not consistently replicated across trials.

Typical doses. When prescribed, DHEA is generally initiated at 25 mg/day for women and 25–50 mg/day for men, with monitoring of DHEA-S, testosterone, and oestradiol to avoid supraphysiological conversion to sex hormones.

Lifestyle and adaptogenic approaches. Before considering supplementation, addressing the drivers of HPA axis dysfunction through sleep, stress reduction, and adaptogenic support for HPA axis represents a reasonable first step in individuals with mildly low DHEA-S attributed to chronic stress rather than confirmed adrenal insufficiency.

DHEA should not be supplemented without confirmed low DHEA-S levels and medical supervision, given the potential for unwanted androgenic or oestrogenic effects from peripheral hormone conversion — particularly in women.

How to Test DHEA-S in Australia

DHEA-S is a standard test available through all major Australian pathology providers including Queensland Health Pathology, Sullivan Nicolaides, and Laverty. Medicare rebates apply under specific clinical criteria — primarily suspected adrenal insufficiency, investigation of virilisation or precocious puberty, or assessment of a suspected adrenal tumour. Outside these indications, testing is typically out of pocket.

Private testing costs approximately $30–50 AUD for DHEA-S alone. Several functional medicine-oriented online pathology requesting services allow Australians to access DHEA-S testing without a specialist referral.

For a comprehensive adrenal and hormonal assessment, a useful panel includes: DHEA-S, morning cortisol (8–9 am), ACTH (if adrenal insufficiency is suspected), total testosterone, SHBG, and a full thyroid panel. If HPA axis dysregulation rather than true adrenal insufficiency is the primary concern, a four-point salivary cortisol and DHEA profile provides a diurnal picture that a single blood draw cannot capture.

Results should be interpreted against age-stratified functional ranges, in context with cortisol and sex hormone status, and ideally tracked over serial measurements rather than evaluated from a single time point.

Clinical Takeaways

DHEA-S is not a niche marker. It is the most abundant steroid hormone in human circulation, the most reliable index of adrenal androgen output, and one of the strongest single predictors of biological age available on a standard blood panel — requiring nothing more than a routine blood draw to measure.

For anyone serious about tracking long-term health, functional capacity, and resilience to physiological stress, DHEA-S deserves a place on the panel. A result that is low for age, declining faster than expected, or accompanied by a high cortisol-to-DHEA-S ratio is a signal worth investigating — not dismissing because it happens to fall somewhere within a reference range designed for a population that largely is not optimising its health.

The goal is not to simply be "within range." It is to understand where you sit relative to what your biology should look like at your age — and to act on that information while the window for intervention remains open.